Ovarian cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BRCA1 20
• BRCA2 13
• PARP 27
• TP53 6
• PD-1 12
• AKT 2
• HER2 16
• PD-L1 7
• PI3K 3
• STAT3 1
• mTOR 0
• VEGF 6
• KRAS 6
• EGFR 3
• PTEN 2
• CTNNB1 0
• FAK 1
• MAPK 0
• MYC 0
• NRF2 0
• CTLA-4 6
• ERK 1
• JAK 0
• STING 0
• GPX4 0
• HIF-1 0
• MEK 1
• TROP2 4
• PALB2 5
• B7-H3 7
• CDK4/6 4
• ATM 1
• CD47 0
• IL-6 0
• EZH2 1
• JNK 0
• PIK3CA 3
• YAP 0
• BCL-2 0
• BRAF 4
• CXCR4 0
• HDAC 0
• PPAR 0
• AMPK 0
• ARID1A 3
• AXL 1
• COX-2 2
• NMDA 0
• TIGIT 0
• AR 0
• CD40 1
• HER3 1
• HMGB1 0
• KEAP1 1
• METTL3 0
• RAS 0
• TLR4 0
• FGFR 0
• PINK1 0
• PKM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 2,388 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

  NCT05075993· M.D. Anderson Cancer Center· Updated 10 Nov 2026

  “\<75% participation”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

  NCT07030907· Outpace Bio, Inc.· Updated 9 Nov 2026

  “Business decision”Registry text, quoted unchanged. Source

• Terminated

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Updated 5 Nov 2026

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Terminated

  AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

  NCT05617755· Arsenal Biosciences, Inc.· Updated 29 Oct 2026

  “Active patients have been rolled over to a separate LTFU study.”Registry text, quoted unchanged. Source

• Terminated

  huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

  NCT05057715· University of Pennsylvania· Updated 29 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  PRO1107 in Patients With Advanced Solid Tumors

  NCT06171789· Genmab· Updated 29 Oct 2026

  “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”Registry text, quoted unchanged. Source

• Withdrawn

  A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

  NCT05479045· Georgetown University· Updated 9 Oct 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Terminated

  Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer

  NCT05833321· Centre Hospitalier Metropole Savoie· Updated 8 Oct 2026

  “recruitement failure”Registry text, quoted unchanged. Source

• Suspended

  Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

  NCT05866679· M.D. Anderson Cancer Center· Updated 6 Oct 2026

  “Suspension”Registry text, quoted unchanged. Source

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Updated 22 Sept 2026

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

  NCT06843447· Merck Sharp & Dohme LLC· Source

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Source

• Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors

  NCT06660654· Daiichi Sankyo Inc.· Source

• A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  NCT06824467· Merck Sharp & Dohme LLC· Source

• A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Merck Sharp & Dohme LLC· Source

• A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

  NCT07743164· Merck Sharp & Dohme LLC· Source

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  NCT01174121· National Cancer Institute (NCI)· Source

• Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

  NCT07504588· National Cancer Institute (NCI)· Source

• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

  NCT04847063· National Cancer Institute (NCI)· Source

• Developing a Gynecologic Cancer Health Promotion Community Engagement Program

  NCT07910162· Abramson Cancer Center at Penn Medicine· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 48
• Organoids 19
• Mendelian Randomization Analysis 28
• CRISPR-Cas Systems 15
• Gene Expression Profiling 126
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 6
• Exome Sequencing 11
• Proteomics 62
• Metabolomics 17
• Mass Spectrometry 6
• Flow Cytometry 26
• Immunohistochemistry 95
• Liquid Biopsy 15
• Circulating Tumor DNA 13
• Xenograft Model Antitumor Assays 234
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 56
• Machine Learning 60
• Deep Learning 35
• Cohort Studies 104
• Genome-Wide Association Study 25

• Deep Learning of Position-Aligned Dynamic Cell Deformation Trajectories for Ovarian Cell Phenotyping in Hyperbolic Microchannels.

  Anal Chem, Oct 2026

• HRDPath: an explainable multi-model deep learning architecture for predicting homologous recombination deficiency from histopathology images.

  Nat Commun, Oct 2026

• iDCF: Interpretable deconvolution of cell fractions via biologically-informed deep learning using scRNA-seq data.

  PLoS Comput Biol, Aug 2026

• STL-DeepBDC: A Robust Few-Shot Learning Framework for Multiclass Ovarian Tumor Classification in Ultrasound Outperforms Conventional Transfer Learning.

  Cancer Med, Aug 2026

• [Medical prior-guided TabMap deep learning model for ovarian cancer prediction and interpretability analysis].

  Nan Fang Yi Ke Da Xue Xue Bao, Jul 2026

• Ovarian Cancer Diagnosis and Chemoresistance Prediction Model Based on cfRNA Molecular Signature.

  Adv Sci (Weinh), Jul 2026

• Real-time intraoperative identification of malignant ovarian tumors using deep learning of clinical gross specimen images.

  Taiwan J Obstet Gynecol, Jul 2026

• Temporal deep learning for 28-day mortality prediction in critically ill ovarian cancer patients: a multicenter development and validation study using hourly vital signs.

  J Ovarian Res, Jun 2026

• Deep learning of pretreatment ascites cytopathology for platinum-resistance risk stratification in advanced epithelial ovarian cancer.

  Neoplasia, Jun 2026

• Deep learning-based prediction of gene expression from histopathology identifies NR5A1 as a candidate biomarker and druggable target in high-grade serous ovarian carcinoma.

  J Ovarian Res, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.